Systemic Immunomodulatory Treatments for Atopic Dermatitis

Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy Phase 3 trial in the United States and Canada (BREEZE-AD5)

(2021) Eric L. Simpson et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis

(2021) Joseph F. Merola et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

(2021) Thomas Bieber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

(2021) Kristian Reich et al.   LANCET

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

(2021) Emma Guttman-Yassky et al.   LANCET

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

(2021) Andrew Blauvelt et al.   JAMA Dermatology

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis

(2020) Emma Guttman-Yassky et al.   JAMA Dermatology

Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis

(2020) Aaron M. Drucker et al.   JAMA Dermatology

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial

(2020) Amy S. Paller et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

(2020) Eric L Simpson et al.   LANCET

Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus

(2020) Kenji Kabashima et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

(2020) Jonathan I. Silverberg et al.   JAMA Dermatology

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis

(2020) Kristian Reich et al.   JAMA Dermatology

Inclusion of Older Adults in Randomized Clinical Trials for Systemic Medications for Atopic Dermatitis

(2020) Megan Lam et al.   JAMA Dermatology

GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions

(2019) Nancy Santesso et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis

(2019) Susan Chan et al.   JAMA Pediatrics

Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis

(2018) Romina Brignardello-Petersen et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials

(2018) Patrick Fleming et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Methotrexate Versus Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial

(2018) Catherine Goujon et al.   Journal of Allergy and Clinical Immunology-In Practice

Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis

(2018) Aaron Mark Drucker et al.   BMJ Open

Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic Review

(2016) Su Golder et al.   PLOS MEDICINE

Unknown

(2016)   ALLERGY

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

(2015) Brian Hutton et al.   ANNALS OF INTERNAL MEDICINE

Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data

(2015) M.K.A. Basra et al.   DERMATOLOGY

The Harmonizing Outcome Measures for Eczema (HOME) Roadmap: A Methodological Framework to Develop Core Sets of Outcome Measurements in Dermatology

(2015) Jochen Schmitt et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Unknown

(2015)   STATISTICS IN MEDICINE

The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials

(2014) Jochen Schmitt et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Guidelines of care for the management of atopic dermatitis

(2014) Robert Sidbury et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis

(2014) M. A. Puhan et al.   BMJ-British Medical Journal

A randomized trial of methotrexate versus azathioprine for severe atopic eczema

(2011) Mandy Elvira Schram et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

(2010) Georgia Salanti et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Checking consistency in mixed treatment comparison meta-analysis

(2010) S. Dias et al.   STATISTICS IN MEDICINE